This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masellis-Smith, A. Articles by Pilarski, L. M. Search for Related Content PubMed PubMed Citation Articles by Masellis-Smith, A. Articles by Pilarski, L. M.

Adhesion of Multiple Myeloma Peripheral Blood B Cells to Bone Marrow Fibroblasts: A Requirement for CD44 and ₄ß₇¹

Departments of Oncology and Medicine, University of Alberta, Edmonton, Alberta T6G 2E1, and The Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada

We have earlier described the presence of phenotypically unusual monoclonal B cells within the peripheral blood of multiple myeloma (MM) patients. To determine the biological properties of these B cells as compared to B cells from normal donors, we investigated the potential of CD19⁺ MM blood B cells to adhere to endothelial cell and bone marrow (BM)-fibroblast monolayers. We find that 30–60% of freshly isolated CD19⁺ MM blood B cells adhere to endothelial cell monolayers, and 50–80% adhere to BM fibroblast monolayers. The adhesion of MM blood B cells to either monolayer was not increased by in vitro activation, suggesting that these cells were activated in vivo. In contrast, fewer than 10% of CD19⁺ B cells from peripheral blood of normal donors adhered. Function-blocking monoclonal antibodies (mAbs) were used to determine which adhesion receptors were involved in CD19⁺ MM blood B cell interaction with BM fibroblasts. mAbs against very late antigen 4, the ß₇-integrin subunit, and CD44, but not mAbs against very late antigen 5 and ß₁, inhibited adhesion 61, 50, and 30%, respectively. The lack of inhibition with mAbs against ß₁ implicates ₄ß₇ but not ₄ß₁ in adhesion of CD19⁺ MM blood B cells. To determine the ₄ß₇ ligand that mediated MM blood B cell adhesion, mAbs against vascular cellular adhesion molecule 1 and fibronectin, as well as CS1 and RGD peptides, were used as inhibitors. These were unable to reduce the adhesion of CD19⁺ MM blood B cells to BM fibroblasts, suggesting that fibronectin and vascular cellular adhesion molecule 1 are not involved in adhesion. Also, adhesion of MM blood B cells to mucosal addressin cell adhesion molecule 1-transfected Chinese hamster ovary cells was not enhanced compared to control-transfected Chinese hamster ovary cells, suggesting that mucosal addressin cell adhesion molecule 1 was not promoting adhesion of these cells. These data implicate CD44:HA interactions, as well as ₄ß₇ and an as yet unidentified ligand in the adhesion of in vivo activated MM blood B cell adhesion to BM fibroblasts. The adhesion properties of MM CD19⁺ B cells distinguishes them from normal B cells. Although the malignant status of these cells is as yet undefined, their adhesion properties implicate MM blood B cells in migratory spread of the disease.

¹ This work was funded by the Alberta Cancer Board Research Initiatives Program and the National Cancer Institute of Canada with funds from the Canadian Cancer Society. A.M-S. was funded by a fellowship from the Alberta Heritage Fund for Medical Research.

² To whom requests for reprints should be addressed. Phone: (403) 432-8925; Fax: (403) 432-8928; E-mail: lpilarsk@gpu.srv.ualberta.ca.

Received 6/26/96. Accepted 1/ 4/97.

This article has been cited by other articles:

				L. Nadav, B.-Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger The Generation and Regulation of Functional Diversity of Malignant Plasma Cells. Cancer Res., September 1, 2006; 66(17): 8608 - 8616. [Abstract] [Full Text] [PDF]

				B. Hoang, L. Zhu, Y. Shi, P. Frost, H. Yan, S. Sharma, S. Sharma, L. Goodglick, S. Dubinett, and A. Lichtenstein Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance Blood, June 1, 2006; 107(11): 4484 - 4490. [Abstract] [Full Text] [PDF]

				L. Li, S.-O. Yoon, D.-D. Fu, X. Zhang, and Y. S. Choi Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055 Blood, August 1, 2004; 104(3): 815 - 821. [Abstract] [Full Text] [PDF]

				A. Calabro, M. M. Oken, V. C. Hascall, and A. M. Masellis Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients Blood, September 18, 2002; 100(7): 2578 - 2585. [Abstract] [Full Text] [PDF]

				T. Michigami, N. Shimizu, P. J. Williams, M. Niewolna, S. L. Dallas, G. R. Mundy, and T. Yoneda Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha 4beta 1-integrin enhances production of osteoclast-stimulating activity Blood, September 1, 2000; 96(5): 1953 - 1960. [Abstract] [Full Text] [PDF]

				K. Asosingh, U. Gunthert, M. H. C. Bakkus, H. De Raeve, E. Goes, I. Van Riet, B. Van Camp, and K. Vanderkerken In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells Cancer Res., June 1, 2000; 60(11): 3096 - 3104. [Abstract] [Full Text] [PDF]

				I. M. S. Dahl, I. Turesson, E. Holmberg, and K. Lilja Serum Hyaluronan in Patients With Multiple Myeloma: Correlation With Survival and Ig Concentration Blood, June 15, 1999; 93(12): 4144 - 4148. [Abstract] [Full Text] [PDF]

				M. Crainie, A. R. Belch, M. J. Mant, and L. M. Pilarski Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants Blood, March 1, 1999; 93(5): 1684 - 1696. [Abstract] [Full Text] [PDF]

				A. J. Szczepek, K. Seeberger, J. Wizniak, M. J. Mant, A. R. Belch, and L. M. Pilarski A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction Blood, October 15, 1998; 92(8): 2844 - 2855. [Abstract] [Full Text] [PDF]

				L. M. Pilarski, A. J. Szczepek, and A. R. Belch Deficient Drug Transporter Function of Bone Marrow-Localized and Leukemic Plasma Cells in Multiple Myeloma Blood, November 1, 1997; 90(9): 3751 - 3759. [Abstract] [Full Text] [PDF]